MedPath

SYMTUZA

SYMTUZA

Approved
DIN Number

02473720

Drug Class

Human

Market Date

Apr 25, 2018

Company
HC

Janssen Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02473720
AIG Number0460090001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AR22 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification08:18.08
Health Canada Classification

ACTIVE INGREDIENTS (4)

COBICISTATActive
Strength: 150 MG
Monograph: COBICISTAT
DARUNAVIR (DARUNAVIR ETHANOLATE)Active
Strength: 800 MG
Monograph: DARUNAVIR (DARUNAVIR ETHANOLATE)
EMTRICITABINEActive
Strength: 200 MG
Monograph: EMTRICITABINE
TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)Active
Strength: 10 MG
Monograph: TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.